Bill · H.R. 9040· House(119-HR-9040)
Regulate the Price of All Drugs Act
- Introduced
- 5/26/2026
- Last activity
- 5/26/2026 — Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Sponsored by
- Brad Sherman
- Cosponsors
- None
- Introduced
- In Committee
What this bill would do
This bill establishes the "Regulate the Price of All Drugs Act" to set fair prices for approved prescription drugs. It creates a Prescription Drug Price Regulatory Commission to recommend prices to the Secretary of Health and Human Services. The Secretary then establishes and publishes these fair prices for individuals, pharmacies, and providers to access. Manufacturers who fail to provide access at these prices face significant civil penalties. The bill also includes provisions for price revisions, temporary waivers, and potential patent licensing actions. Additionally, it allows the use of the Defense Production Act to increase domestic drug supplies when necessary.
Yes· 3 of 11
Does this lower the price of prescription medicines?+9
The bill establishes a regulatory mechanism to cap the prices of approved prescription drugs at a determined fair price.
Would households on low incomes be better off under this?+7
Reducing drug costs provides significant relief to households with limited income.
Does this give the federal government more power?+7
The bill significantly expands the authority of the Secretary of Health and Human Services and the President via the Defense Production Act.
The opposite
Does this make patent and copyright rules fairer?-6
The bill allows the government to claim licenses from existing drug patents if manufacturers do not comply with pricing rules.
Is this likely to grow the economy?-2
The bill's potential to impact patent exclusivity and revenue for manufacturers could dampen private investment in drug development.
Who it would affect, and how
Potential Positive Impacts for People
-
Access to Affordable Drugs: The bill establishes fair prices that must be provided to any "fair price eligible individual" (Section 2(a)(1)(A); Section 3(a)(1)).
-
Price Protections for Providers: Hospitals, physicians, and other providers can access drugs at the established fair prices (Section 2(a)(1)(B); Section 3(a)(2)).
-
Protection Against Excessive Pricing: The bill prohibits selling or offering for sale a drug at a price that exceeds the published fair price (Section 4(a)).
-
Consumer Recourse: Individuals injured by violations of the pricing rules may bring a private action in court to seek damages or an injunction (Section 4(d)(1)).
-
State-Level Protections: State attorneys general may bring civil actions on behalf of residents if their interests are threatened by pricing violations (Section 4(c)(1)).
-
Ensuring Drug Availability: The President can use the Defense Production Act to increase the domestic supply of drugs if there are inadequate facilities or unreliable foreign supplies (Section 6).
Potential Negative Impacts for People
-
Financial Penalties for Manufacturers: Companies that do not provide access to the fair price are subject to civil penalties equal to 10 times the difference between the price charged and the fair price (Section 3(d)(1)).
-
Risk to Patent Ownership: The Secretary of Health and Human Services may claim a license—which can be exclusive—from a patent owner if the drug is sold above the fair price or if there is inadequate supply (Section 5).
-
Potential for Price Changes: The Secretary has the authority to revise established fair prices due to changes in supply or demand (Section 3(b)).
-
Limited Price Consistency: The Secretary may authorize temporary waivers allowing manufacturers to sell drugs at prices higher than the established fair price (Section 3(c)(1)).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Demographic And Interest Groups
- Good For Low Income Households+7Good For Seniors+6Good For Middle Class Households+5Good For Union Workers+3
- Healthcare
- Reduces Prescription Drug Costs+9Improves Healthcare Access+6
- Governance And Ideology
- Increases Federal Power+7Improves Government Transparency+5
- Education And Technology
- Improves Intellectual Property Fairness-6
- Economy And Finance
- Improves Consumer Protection+7Improves Economic Growth-2
- National Security And Foreign Policy
- Improves Veterans Benefits+5
- Social Issues And Justice
- Improves Poverty Reduction+4
- 5/26/2026
- Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Introduced in House